Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 12/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9151061 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8761679 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8748944 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL3425106 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8761610 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8748862 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8761736 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8749215 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8754825 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 | |
| SCHEMBL8748934 | 1.00 | MEN1 (0.51) | MEN1KMT2APOLBPTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0342056-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1994-08-17 | — | — | EP | claimed |
| EP-0277428-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1994-03-23 | — | — | EP | claimed |
| EP-0342055-B1 | Use of pyroglutamic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis | UNILEVER PLC (GB) | 1994-01-12 | — | — | EP | claimed |
| EP-0342054-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1993-11-03 | — | — | EP | claimed |
| US-5118692-A | Penetration enhances for transdermal delivery of systemic agents | WHITBY RESEARCH, INC. (US) | 1992-06-02 | — | — | US | claimed |
| US-5118676-A | Administering carboxylic derivatives as enhancer with systemically active agents | WHITBY RESEARCH, INC. (US) | 1992-06-02 | — | — | US | claimed |
| WO-1989011275-A1 | PENETRATION ENHANCERS FOR TRANSDERMAL DELIVERY OF SYSTEMIC AGENTS | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1989-11-30 | — | — | WO | claimed |
| EP-0342054-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | claimed |
| EP-0342055-A2 | Use of pyroglutamic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | claimed |
| EP-0342056-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | claimed |
| EP-0277428-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1988-08-10 | — | — | EP | claimed |
| US-12589095-B2 | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient | PRIMO PHARMATECH LLC (US) | 2026-03-31 | — | — | US | disclosed |
| US-12558312-B2 | Solid dosage form for transmucosal drug delivery | PRIMO PHARMATECH LLC (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3735988-B1 | SUBLINGUAL FILMS | SUMITOMO PHARMA AMERICA INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4578461-A2 | METHODS OF TREATING PARKINSONS DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA | Sumitomo Pharma America, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-0334586-A1 | Carbohydrate lactam derivatives and their use in cosmetic compositions | UNILEVER PLC (GB) | 1989-09-27 | — | — | EP | disclosed |
| US-4832946-A | CELL CULTURE FOR HAIR GROWTH | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC., A CORP. OF NY | 1989-05-23 | — | — | US | disclosed |
| EP-0295092-A2 | Skin treatment composition | UNILEVER PLC (GB) | 1988-12-14 | — | — | EP | disclosed |
| EP-0277428-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1988-08-10 | — | — | EP | disclosed |
| EP-0272920-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589095-B2 | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient | OXTR, CCKBR, HTR2B | MEN1 971/4885KMT2A 4082/4885POLB 3383/4885 |
| US-12558312-B2 | Solid dosage form for transmucosal drug delivery | AANAT, MTNR1B, CHLSN | MEN1 378/4885KMT2A 2264/4885POLB 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.